Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

5 Things Constellation Brands Just Said About Canopy Growth -- Good and Bad

By Keith Speights - Jul 2, 2019 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what the big alcoholic beverage maker likes -- and doesn't like -- about its Canadian cannabis partner.

Constellation Brands ( STZ 1.28% ) announced its first-quarter earnings results last Friday, and they were better than Wall Street's expectations. The alcoholic beverage maker's results were dragged down, though, by its investment in cannabis producer Canopy Growth ( CGC 4.83% ). Without the Canopy investment, Constellation would have posted a nice profit. With Canopy, the company reported a $245 million loss in the quarter.

You might think that Constellation Brands' executives would have some negative comments about Canopy Growth. And they did. But they also expressed a lot of optimism about their cannabis partner. Here are five important things they had to say about Canopy Growth during their Q1 conference call.

Hand cupped over ear

Image source: Getty Images.

1. They are "not pleased" with Canopy's latest results

No, CEO Bill Newlands didn't call Canopy Growth a cannabis albatross hanging around his company's neck. However, he did say that Constellation was "not pleased with Canopy's recent reported year-end results." Canopy posted a huge net loss in fiscal 2019 Q4, along with a quarter-over-quarter decline in Canadian recreational and medical cannabis sales, and lower international medical cannabis sales.

About the only truly good news from Canopy's Q4 results was that its total revenue increased. But that increase resulted primarily from the acquisition of German vaporizer device maker Storz & Bickel.  

2. They're positive on Canopy's acquisition deals

Constellation CFO David Klein said that "we're very happy with [Canopy's] investment in Storz & Bickel." He noted the positive impact from this acquisition in Canopy's latest results, but Constellation sounded even more positive about Canopy's deal to acquire U.S.-based cannabis operator Acreage Holdings.

Newlands brought up Canopy's agreement to buy Acreage in his introductory comments in the earnings call, saying, "We're excited about this opportunity, as it provides a path for Canopy to have a leading position in the U.S. upon federal cannabis reform." He added that the transaction extends the duration of Constellation's Canopy warrants, a plus that he said "provides long-term financial flexibility for cash deployment to our shareholders."

3. They expect around $1 billion in annualized revenue from Canopy soon

Despite Canopy's weaker-than-expected sales in its fiscal Q4, Constellation remains confident in the cannabis producer's long-term potential. In fact, Newlands said that his company continues to expect that Canopy will deliver an annualized top-line run rate of around $1 billion by the end of its next fiscal year, which ends on March 31, 2020.

In Canopy's Q4 conference call, co-CEO Bruce Linton stated that he thinks the $1 billion annualized revenue rate is achievable as well. There are variables that could impact hitting this goal, though, including how quickly retail stores open in Canadian provinces (especially Ontario) and how smoothly the launch goes for cannabis edibles and other derivative products.

4. They support Canopy's move into the U.S. hemp CBD market

While Constellation looks forward to working with Canopy to introduce new higher-margin form factors -- including vapes, beverages, and edibles -- in Canada later this year, the company also eagerly anticipates Canopy's entrance into the U.S. hemp cannabidiol (CBD) market. Canopy is building a large-scale hemp production center in New York state. Newlands echoed the comments from Bruce Linton in Canopy's Q4 conference call that Canopy will market CBD products in the U.S. by the end of 2019.

In his remarks about Canopy's entrance into the U.S. hemp CBD market, Constellation's Klein said, "We think that's a good place for them to focus their money and resources to really take advantage of what could be a very large and profitable market in the U.S." adding that his company is "really happy with how they're positioning themselves there."

5. They remain "very bullish"

Could Constellation regret its decision to invest over $4 billion in Canopy Growth? Its executives say they don't.

Newlands stated that Constellation "remain[s] happy with our investment in the cannabis space and its long-term potential." Klein seconded this, saying, "We still are very bullish on our Canopy investment, and we're very happy we made the investment when we did into this space."

While Canopy is hurting Constellation's bottom line right now, it's a leader in the global cannabis market. And that market is likely to grow exponentially over the next decade. Also, Constellation has recognized a pre-tax net gain of $1.6 billion since its first investment in Canopy in November 2017. That's a pretty good return so far -- and likely a key reason Constellation continues to be happy overall with Canopy Growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
STZ
$233.83 (1.28%) $2.96
Canopy Growth Stock Quote
Canopy Growth
CGC
$10.64 (4.83%) $0.49
Acreage Holdings, Inc. Stock Quote
Acreage Holdings, Inc.
ACRGF

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.